How to access Talzenna from India — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Indian patient diagnosed with germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer may receive a prescription for Talzenna (talazoparib) from their treating medical oncologist after BRCA testing confirms the mutation. Talzenna is also FDA-approved in combination with enzalutamide for certain metastatic castration-resistant prostate cancer settings. In India, Talzenna may not be routinely stocked in hospital pharmacies, which is why your oncologist may be coordinating a personal-import pathway on your behalf.
This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Talzenna is an oral PARP inhibitor. Eligibility for the breast cancer indication requires a germline BRCA1/2 mutation in HER2-negative advanced disease; in prostate cancer, specific HRR alterations or BRCA status are required. The manufacturer is Pfizer. Dosing is typically 1 mg orally once daily (with dose adjustments for renal impairment). Monitoring includes complete blood count (anaemia is common), renal function, and myelodysplastic syndrome / acute myeloid leukaemia surveillance. Your oncologist will confirm BRCA status and sequencing against your overall treatment plan.
Is Talzenna legally importable into India?
Yes — through the personal-import provision recognised under the Drugs and Cosmetics Act and the framework administered by the Central Drugs Standard Control Organization (CDSCO). The framework allows a patient, through their treating physician, to import a quantity of a medicine for personal use when the medicine has been approved by a recognised foreign regulator (FDA qualifies) and is prescribed for their named clinical need.
The named-patient mechanism rests on four anchors: (a) the medicine is approved by a recognised reference authority such as the FDA, (b) no clinically equivalent locally registered alternative is suitable for the patient, (c) the treating physician takes clinical responsibility for use, and (d) the importing party documents chain of custody from the US source to the patient. Supporting documentation typically includes the physician's prescription, a clinical rationale letter, and customs declaration.
How the pathway works, step by step
- Consultation with your treating oncologist. The decision to prescribe Talzenna is clinical, based on BRCA status and treatment line. Your oncologist documents the rationale.
- Prescription and clinical rationale letter. Your physician issues a prescription naming Talzenna and the planned duration.
- Personal-import documentation. Reserve Meds prepares the personal-import package for customs clearance, including the physician letter, prescription, patient identifier, and product chain-of-custody.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from the manufacturer's authorised distribution chain under DSCSA.
- Temperature-controlled shipment. Talzenna is a stable oral capsule; shipments travel with tamper-evident packaging and customs documentation end to end.
- Arrival and dispensing support. Your oncologist remains the treating clinician. Reserve Meds coordinates re-supply ahead of cycle end to avoid treatment gaps.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming BRCA status, tumour type, prior therapies, and Talzenna as the indicated treatment
- Verification of their Indian medical registration (state medical council)
- A current prescription naming the product, strength, and quantity
- Patient identifier (anonymised reference where possible)
- The planned treatment cadence (continuous daily therapy with monthly re-supply)
Reserve Meds provides a physician documentation kit bundling the templates Indian customs and CDSCO reviewers expect to see for personal-import of oncology oral therapies.
Costs and timing
Talzenna's US cash-pay reference price for a 30-day supply sits in an indicative 2026 range of roughly USD 19,000–22,000. Logistics, customs handling, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake.
Indicative timing — not guaranteed — for first shipment arrival after cohort intake opens is approximately 14–28 days from the moment a complete dossier is assembled. Subsequent re-supply cycles are generally faster once the pathway is established.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Talzenna specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Personal-import documentation package for your physician and for Indian customs handling.
- Logistics. Temperature-stable shipment coordination and customs clearance support.
- Concierge case lead. A named point of contact for your family and your physician throughout the process.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating oncologist. We operate on a waitlist basis during our pre-launch phase.
Frequently asked
Is this legal in India? Yes, when executed through the personal-import provision under the Drugs and Cosmetics Act with appropriate physician documentation. See our trust and compliance page for our methodology.
Is Talzenna different from Lynparza? Both are PARP inhibitors with different dosing, potency profiles, and approved indications. Your oncologist will choose based on tumour type, line of therapy, and tolerability profile. We do not advise on this choice.
What about anaemia management? Anaemia is the most common Talzenna toxicity and often requires dose modification or transfusion support. Your oncologist will manage this; we coordinate supply, not clinical management.
Will private insurance cover this? Cash-pay is the default. Some Indian private insurers reimburse named-patient imports on case-by-case approval; we supply documentation for your submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Talzenna coordination in India.
Add me to the Talzenna waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.